跳到正文
MarketHOT
English
摘要
SEC · EDGAR 财务披露·· 13 天前AI 评分31

Braveheart Bio 提交 8-K,披露 HRS/BHB-1893 研究数据发布

Braveheart Bio, Inc. (0002131524) (Filer)

AI 导读

Braveheart Bio 于 11 月 6 日提交 8-K,披露公司发布了关于 Hengrui Pharma 与 Braveheart Bio 在美国心脏协会科学会议上展示 HRS/BHB-1893 阻塞性肥厚型心肌病 II 期研究 52 周开放标签延长期数据的新闻稿。新闻稿作为附件 99.1 随文件提供。

正文

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

______________________

FORM 8-K

______________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2026

______________________

Braveheart Bio, Inc.

(Exact name of Registrant as Specified in Its Charter)

______________________

Delaware001-4343299-2981994
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)(IRS Employer
Identification No.)

One Letterman Drive, Building A, Suite A4-300

San Francisco, CA

94129
(Address of Principal Executive Offices)(Zip Code)

Registrant’s Telephone Number, Including Area Code: 415-707-6312

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

______________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading
Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share    BRVEThe Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


Item 7.01 Regulation FD Disclosure.

On November 6, 2026, Braveheart Bio, Inc. (the “Company”) issued a press release titled “Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026.” A copy of the press release in connection with this announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in Item 7.01 of this Current Report on Form 8-K, including the accompanying Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1

Press Release issued by Braveheart Bio, Inc. on November 6, 2026, furnished herewith.

104Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Braveheart Bio, Inc.
Date:November 6, 2026By: /s/ J. Paul Rickey
Name:J. Paul Rickey
Title:Chief Financial Officer

来源:SEC EDGAR · 本站存档